Secretin Infusion for Pain Due to Chronic Pancreatitis

This study has been completed.
Dartmouth-Hitchcock Medical Center
Information provided by (Responsible Party):
ChiRhoClin, Inc. Identifier:
First received: December 22, 2010
Last updated: February 11, 2013
Last verified: February 2013

December 22, 2010
February 11, 2013
December 2010
December 2011   (final data collection date for primary outcome measure)
Improvement of Pain Control [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
Same as current
Complete list of historical versions of study NCT01265875 on Archive Site
Safety of intravenous secretin administration at dosages higher then currently approved. [ Time Frame: 30 Days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Secretin Infusion for Pain Due to Chronic Pancreatitis
Secretin Infusion for Pain Due to Chronic Pancreatitis
  • To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
  • To validate the safety of intravenous secretin administration at the dosage indicated in this study.
Not Provided
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Pain Due to Chronic Pancreatitis
Drug: Human Secretin
Dose Escalation
Other Name: ChiRhoStim
human secretin
Intervention: Drug: Human Secretin
Levenick JM, Andrews CL, Purich ED, Gordon SR, Gardner TB. A phase II trial of human secretin infusion for refractory type B pain in chronic pancreatitis. Pancreas. 2013 May;42(4):596-600. doi: 10.1097/MPA.0b013e318273f3ec.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female, between the ages of 18-70 years old.
  2. Documented chronic pancreatitis as determined by CT scan, endoscopic ultrasound, MRCP and/or pancreatic function tests.
  3. If female, and not more than 1 year post-menopausal or surgically sterile, must use medically acceptable form of contraception or abstain from sexual activity during the study. Acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to Screening Visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence.
  4. If a female of reproductive potential, receive counseling on pregnancy protection and effective contraception within 30 days prior to dosing with secretin.
  5. Negative serum pregnancy within 72 hours of secretin administration.
  6. Use of opioid analgesics for chronic pain from CP.
  7. Willing and able to sign written informed consent.

Exclusion Criteria:

  1. Male or female <18 or >70 years of age.
  2. Abnormal serum amylase and/or lipase indicative of acute pancreatitis within 30 days of study enrollment.
  3. Exhibiting signs and/or symptoms of an episode of acute pancreatitis.
  4. Severe cardiac disease (stable or unstable angina, congestive heart failure, uncontrolled arrhythmias, implantable defibrillator, severe valvular disease, etc).
  5. Severe pulmonary disease (COPD, severe asthma, interstitial lung disease, etc).
  6. Severe renal disease (history of acute or chronic renal failure, dialysis dependent, baseline creatinine >2.0 mg/dL).
  7. Previous adverse drug event to intravenous secretin.
  8. Ongoing illicit drug use or abuse.
  9. Ongoing moderate or severe alcohol use defined as greater than 8 oz beer, 8 oz wine and/or 1 oz liquor /day.
  10. Acute pancreatitis as defined by the Atlanta Classification definition (refer to Table 1) within the previous two months or symptoms consistent with ongoing acute pancreatitis.
  11. Prior pancreatic surgery.
  12. Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception.
  13. Use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides within 30 days prior to Visit 1.
  14. Any medical condition which, in the judgment of the investigator, renders participation in this study medically inadvisable.
  15. Participation in an investigational clinical study for a drug or medical device within 30 days prior to Visit 1.
  16. Unwilling or unable to give written, informed consent.
18 Years to 70 Years
Contact information is only displayed when the study is recruiting subjects
United States
ChiRhoClin, Inc.
ChiRhoClin, Inc.
Dartmouth-Hitchcock Medical Center
Principal Investigator: Timothy B Gardner, M.D. Dartmouth-Hitchcock Medical Center
ChiRhoClin, Inc.
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP